Want to see PTN full AI Analyst Report?

Palatin Technologies (PTN) Price & Analysis

2,936 Followers

PTN Stock Chart & Stats

$16.05

Market closed

$16.05

Day’s Range― - ―

52-Week Range$5.00 - $31.00

Previous CloseN/A

VolumeN/A

Average Volume (3M)2.99K

Market Cap

$13.66M

Enterprise Value$58.27

Total Cash (Recent Filing)$10.16M

Total Debt (Recent Filing)$286.66K

Price to Earnings (P/E)―

Beta-0.19

Next Earnings

Nov 16, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-4.66

Shares Outstanding1,779,275

10 Day Avg. Volume2,746

30 Day Avg. Volume2,993

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)-0.79

Price to Sales (P/S)0.00

P/FCF Ratio-0.18

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit<0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$47.50

Price Target Upside195.95% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-2.31

Revenue Forecast (FY)$12.50M

Bulls Say, Bears Say

Bulls Say

Partnership-driven Non-dilutive FundingMaterial upfronts and sublicensing payments provide near-term non-dilutive capital and validate external interest in Palatin’s platform. Structurally this reduces immediate dilution risk, funds IND-enabling work, and creates contingent milestone/royalty upside tied to partner commercialization success.

Lead Peptide MC4R Program Nearing Regulatory FilingA targeted regulatory submission window and active IND-enabling work represent a durable program de-risking milestone. Advancing a lead clinical asset toward filing strengthens future commercialization optionality, increases the chance of partner interest, and shifts value creation from preclinical to regulatory execution.

Low Financial LeverageVery low debt limits interest burden and reduces near-term solvency risk, giving management flexibility to fund R&D and pursue partnering without high fixed financing costs. Structurally this preserves optionality for licensing or staged financings rather than immediate distress-driven outcomes.

Bears Say

Persistent Cash Burn And Limited RunwaySustained negative operating and free cash flow requires ongoing external funding; company guidance indicates cash plus expected receivables only cover operations to mid-2027. This structural liquidity gap raises dilution and execution risks if milestone receipts or financing are delayed or reduced.

Small, Volatile Revenue With Recurring LossesRevenue concentration and variability tied to occasional collaboration receipts produce an unstable top line that cannot currently absorb fixed R&D and G&A. Persistent large operating losses versus a small revenue base mean long-term viability depends on consistent commercial scale or repeat partner milestones.

Pipeline Timing, Competitive And Clinical RiskDelays to oral INDs, deprioritization of prior candidates, and an existing approved competitor compress market opportunity windows. Clinical uncertainties (e.g., hyperpigmentation) mean regulatory and commercial outcomes remain uncertain, increasing the chance of extra trials, slower uptake, or narrower labels.

Palatin Technologies News

What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare-Obesity Opportunity

WSW, NY, July 22nd, 2026, FinanceWire Ten billion dollars. That is what Vertex Pharmaceuticals (Nasdaq:VRTX) agreed to pay...

8d ago

PTN

CRNX

Palatin Technologies Is Pursuing the Next Generation of MC4R. Rhythm Just Reinforced Why That Matters

WSW, NY, June 17th, 2026, FinanceWire Rhythm’s latest rare-obesity win strengthens the MC4R thesis – making Palatin’s more...

1M ago

LLY

NVO

Palatin Technologies Voluntarily Transfers Stock Listing to Nasdaq

Palatin Technologies ( ($PTN) ) has issued an announcement. Palatin Technologies, Inc., a biopharmaceutical developer of melanocortin receptor–targeted...

2M ago

PTN

Palatin announces approval of its common stock by Nasdaq

Palatin (PTN) Technologies announced that its common stock has been approved for listing on the Nasdaq Capital Market...

2M ago

PTN

Palatin price target lowered to $47.50 from $50 at Alliance Global

Alliance Global lowered the firm’s price target on Palatin (PTN) to $47.50 from $50 and keeps a Buy...

3M ago

PTN

Palatin Technologies Earnings Call: Partnerships, Progress, Risks

Palatin Technologies, Inc. (($PTN)) has held its Q3 earnings call. Read on for the main highlights of the...

3M ago

PTN

Palatin Is Betting on the Next Generation of Obesity Drugs (NYSE: PTN)

WSW, NY, May 13th, 2026, FinanceWire In 2012, Novo Nordisk (NYSE:NVO) had a once-weekly version of liraglutide, the...

3M ago

NVO

PTN

Palatin’s Case Strengthens as Rhythm’s FDA Approval Validates Hypothalamic Obesity Market (PTN)

WSW, NY, March 20th, 2026, FinanceWire The FDA’s approval of Rhythm Pharmaceuticals’ IMCIVREE (NASDAQ:RYTM) for acquired hypothalamic obesity...

4M ago

PTN

RYTM

Palatin Technologies’ Rare-Obesity Strategy Sets Up a Catalyst-Rich 2026 for Its MC4R Pipeline (NYSE: PTN)

WSW, NY, February 18th, 2026, FinanceWire Palatin Technologies (NYSE: PTN) today reported its Q4 2025 financial results and...

5M ago

PTN

Palatin Earnings Call: Cash Rebuilt, Obesity Bets Rising

Palatin (($PTN)) has held its Q2 earnings call. Read on for the main highlights of the call. Palatin’s...

5M ago

PTN

Palatin Technologies Inc trading resumes

11:22 EST Palatin (PTN) Technologies Inc trading resumes Published first on TheFly – the ultimate source for real-time,...

8M ago

PTN

Palatin Technologies Inc trading halted, volatility trading pause

11:17 EST Palatin (PTN) Technologies Inc trading halted, volatility trading pause Published first on TheFly – the ultimate...

8M ago

PTN

Palatin initiated with a Buy at LaidlawRhythm Pharmaceuticals

Laidlaw initiated coverage of Palatin with a Buy rating and $60 price target. Palatin (PTN) is a clinical...

8M ago

PTN

RYTM

Palatin initiated with a Buy at Alliance Global

Alliance Global initiated coverage of Palatin (PTN) with a Buy rating and $50 price target Palatin utilizes its...

8M ago

PTN

PTN FAQ

What was Palatin Technologies’s price range in the past 12 months?

Palatin Technologies lowest stock price was $5.00 and its highest was $31.00 in the past 12 months.

What is Palatin Technologies’s market cap?

Palatin Technologies’s market cap is $13.66M.

When is Palatin Technologies’s upcoming earnings report date?

Palatin Technologies’s upcoming earnings report date is Nov 16, 2026 which is in 109 days.

How were Palatin Technologies’s earnings last quarter?

Palatin Technologies released its earnings results on May 13, 2026. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$1.243 by $0.873.

Is Palatin Technologies overvalued?

According to Wall Street analysts Palatin Technologies’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Palatin Technologies pay dividends?

Palatin Technologies does not currently pay dividends.

What is Palatin Technologies’s EPS estimate?

Palatin Technologies’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Palatin Technologies have?

Palatin Technologies has 1,779,275 shares outstanding.

What happened to Palatin Technologies’s price movement after its last earnings report?

Palatin Technologies reported an EPS of -$0.37 in its last earnings report, beating expectations of -$1.243. Following the earnings report the stock price went down -16.011%.

Which hedge fund is a major shareholder of Palatin Technologies?

Currently, no hedge funds are holding shares in PTN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Palatin Technologies

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.

Palatin Technologies (PTN) Earnings & Revenues

Historic Earnings Reports

PTN Earnings Call

Q3 2026

0:00 / 0:00

Earnings Call Sentiment|Neutral

Balanced: The call highlighted meaningful near-term commercial validation via upfront collaboration revenue, materially reduced net loss, reduced operating cash burn, strong partnership-driven non-dilutive funding and clear progress across peptide and oral MC4R programs (including IP development). Offsetting these positives are increased operating costs, a limited cash runway to mid-2027 that creates funding risk, a deprioritized earlier oral candidate and timing/competitive risks (notably Rhythm's approved product). Clinical risk around hyperpigmentation and the need for further IND/clinic-readout milestones keep the outlook cautious.View all PTN earnings summaries

PTN Stock 12 Month Forecast

Average Price Target

$47.50

▲(195.95% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","48":"$48","15.75":"$15.75","26.5":"$26.5","37.25":"$37.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":47.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$47.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":47.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$47.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":47.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$47.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,15.75,26.5,37.25,48],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.33,13.18923076923077,16.048461538461538,18.907692307692308,21.766923076923078,24.626153846153848,27.485384615384618,30.344615384615388,33.20384615384616,36.06307692307693,38.9223076923077,41.78153846153847,44.64076923076923,{"y":47.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.33,13.18923076923077,16.048461538461538,18.907692307692308,21.766923076923078,24.626153846153848,27.485384615384618,30.344615384615388,33.20384615384616,36.06307692307693,38.9223076923077,41.78153846153847,44.64076923076923,{"y":47.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.33,13.18923076923077,16.048461538461538,18.907692307692308,21.766923076923078,24.626153846153848,27.485384615384618,30.344615384615388,33.20384615384616,36.06307692307693,38.9223076923077,41.78153846153847,44.64076923076923,{"y":47.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.38,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":9.05,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":9.5,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":7.85,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6.65,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19.97,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.38,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.25,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.45,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.2,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.23,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.61,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.33,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >